Gastroenterology
Volume 128, Issue 1 , Pages 164-168 , January 2005

Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: A safe and effective therapy?

  • Christian Kuntzen

      Affiliations

    • Department of Medicine II, University Hospital of Munich-Grosshadern, Munich, Germany
    • C.K. and V.G. share first authorship.
    • ,
  • Veit Gülberg

      Affiliations

    • Department of Medicine II, University Hospital of Munich-Grosshadern, Munich, Germany
    • Corresponding Author InformationAddress requests for reprints to: Veit Gülberg, MD, Department of Medicine II, University of Munich-Grosshadern, Marchioninistrasse 15, D-81377 Munich, Germany.fax: (49) 89 7095 2392.
    • C.K. and V.G. share first authorship.
    • ,
  • Alexander L. Gerbes

      Affiliations

    • Department of Medicine II, University Hospital of Munich-Grosshadern, Munich, Germany

Received 15 April 2004 ,Accepted 26 August 2004.

References 

  1. Krowka MJ . Hepatopulmonary syndrome versus portopulmonary hypertension (distinctions and dilemmas) . Hepatology . 1997;25:1282–1284
  2. Blendis L , Wong F . Portopulmonary hypertension (an increasingly important complication of cirrhosis) . Gastroenterology . 2003;125:622–624
  3. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation (a prospective study) . Hepatology . 2003;37:401–409
  4. Benjaminov FS , Prentice M , Sniderman KW , Siu S , Liu P , Wong F . Portopulmonary hypertension in decompensated cirrhosis with refractory ascites . Gut . 2003;52:1355–1362
  5. Budhiraja R , Hassoun PM . Portopulmonary hypertension (a tale of two circulations) . Chest . 2003;123:562–576
  6. Krowka MJ , Plevak DJ , Findlay JY , Rosen CB , Wiesner RH , Krom RA . Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation . Liver Transpl . 2000;6:443–450
  7. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension (a report of the multicenter liver transplant database) . Liver Transpl . 2004;10:174–182
  8. Hoeper MM , Galie N , Simonneau G , Rubin LJ . New treatments for pulmonary arterial hypertension . Am J Respir Crit Care Med . 2002;165:1209–1216
  9. Kojima H, Sakurai S, Kuriyama S, Yoshiji H, Imazu H, Uemura M, et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo . J Hepatol . 2001;34:805–811
  10. Gerbes AL , Møller S , Gülberg V , Henriksen JH . Endothelin-1 and -3 plasma concentrations in patients with cirrhosis (role of splanchnic and renal passage and liver function) . Hepatology . 1995;21:735–739
  11. Zhang B, Calmus Y, Wen L, Sogni P, Lotersztajn S, Houssin D, et al. Endothelin-1 induces liver vasoconstriction through both ETA and ETB receptors . J Hepatol . 1997;26:1104–1110
  12. Møller S , Gülberg V , Henriksen JH , Gerbes AL . Endothelin-1 and endothelin-3 in cirrhosis (relations to systemic and splanchnic haemodynamics) . J Hepatol . 1995;23:135–144
  13. Gülberg V , Gerbes AL . Endothelin and systemic, renal and hepatic hemodynamic disturbances in cirrhosis . In:  Arroyo V ,  Gines P ,  Rodes J ,  Schrier RW editor. Ascites and renal dysfunction in liver disease . 2nd ed.. Oxford: Blackwell Publishing; 2005; in press
  14. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension (a randomised placebo-controlled study) . Lancet . 2001;358:1119–1123
  15. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension . N Engl J Med . 2002;346:896–903
  16. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ, et al. Portopulmonary hypertension and the liver transplant candidate . Transplantation . 1999;67:1087–1093
  17. Luo B , Abrams GA , Fallon MB . Endothelin-1 in the rat bile-duct ligation model of hepatopulmonary syndrome (correlation with pulmonary dysfunction) . J Hepatol . 1998;29:571–578
  18. Gandhi CR , Sproat LA , Subbotin VM . Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats . Life Sci . 1996;58:55–62
  19. Leivas A, Jimenez W, Bruix J, Boix L, Bosch J, Arroyo V, et al. Gene expression of endothelin-1 and ET(A) and ET(B) receptors in human cirrhosis (relationship with hepatic hemodynamics) . J Vasc Res . 1998;35:186–193
  20. Møller S , Emmeluth C , Henriksen JH . Elevated circulating plasma endothelin-1 concentrations in cirrhosis . J Hepatol . 1993;19:285–290
  21. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension . Circulation . 2000;102:411–418
  22. Soper CP , Latif AB , Bending MR . Amelioration of hepatorenal syndrome with selective endothelin-A antagonist . Lancet . 1996;347:1842–1843
  23. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump (a potential mechanism for hepatic adverse reactions) . Clin Pharmacol Ther . 2001;69:223–231

PII: S0016-5085(04)01574-4

doi: 10.1053/j.gastro.2004.09.005

Gastroenterology
Volume 128, Issue 1 , Pages 164-168 , January 2005

Article Tools

* Image Usage & Resolution